Dusek, Capuciati and Blue of Studley handle 14,000 s/f lease expansion

Only two months after having renewed its 98,000 s/f headquarters lease at 521-33 West 57th St., Genzyme, has exercised its option to expand by an additional 14,000 s/f. The expansion, on part of the fourth floor, now gives Genzyme a 112,000 s/f anchor position in the building. International commercial real estate services firm Studley's David Dusek, senior managing director, Peter Capuciati, executive VP and Alex Blue, managing director, represented Genzyme, negotiating for the additional space to be co-terminus with the 10-year July renewal. "We anticipated Genzyme would act on its expansion option, but perhaps not this rapidly," said Dusek, "Since growth is part of the company's long-term strategic plan." Established in 1981, Genzyme employs more than 11,000, serves patients in over 100 countries and manufactures products focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune disease, and diagnostic testing. As of 2008, revenues were $4.6 billion. In 2007, the company received the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. About Studley. Studley is the only global tenant advisory firm with a pure tenant representation delivery platform. Founded in 1954, Studley pioneered this conflict-free business model. Today, with 19 offices nationwide and an international presence through its London office and AOS Studley throughout Europe, Studley provides strategic real estate consulting services to top-tier corporations, law firms, nonprofits, government agencies and institutions of higher education. Information about Studley is available at www.studley.com.